Yamnia I Cortés1, Nancy Reame1, Cosmina Zeana2, Haomiao Jia1, David C Ferris3, Elizabeth Shane4, Michael T Yin4. 1. 1 Columbia University School of Nursing , New York, New York. 2. 2 Bronx-Lebanon Hospital Center , Bronx, New York. 3. 3 Department of Medicine, Mt Sinai St. Luke's and Mt Sinai Roosevelt , New York, New York. 4. 4 Department of Medicine, Columbia University College of Physicians and Surgeons , New York, New York.
Abstract
OBJECTIVE: To characterize and compare cardiovascular disease (CVD) risk in HIV-infected and uninfected postmenopausal minority women using the Framingham Risk Score (FRS) as an assessment measure. METHODS: A cross-sectional analysis was performed in 152 (109 HIV+, 43 HIV-) subjects from an existing study cohort of postmenopausal Hispanic and African American women. Data necessary to calculate FRS and menopause features were retrieved by retrospective chart review. Bivariate statistics was used to compare CVD risk factors. Multivariable linear regression was used to determine factors associated with FRS in HIV-infected women. RESULTS: The HIV-infected group was younger, less obese, and with lower rates of diabetes versus controls. In a subset of age-matched participants, median FRS did not differ between groups (14.6 [IQR = 9.1, 21.6] vs. 15.5 [IQR = 12.3, 22.1]; p = 0.73). Fourteen percent of HIV-infected women meeting criteria for the low-risk FRS category (<10%) had a history of CVD, a similar rate as controls. HIV-infected women at intermediate/high CVD risk had higher rates of surgical menopause. According to 2013 clinical guidelines, more than half of HIV-infected women not prescribed statin therapy (52%) were eligible for treatment; however, statin therapy was similarly under-prescribed in uninfected women. CONCLUSIONS: In this study, CVD risk as assessed by the FRS was not significantly different by HIV status. Performance of the FRS may be compromised in postmenopausal HIV-infected minority women. HIV-infected and uninfected women may be undertreated with statin therapy. Large longitudinal cohorts and inclusion of subclinical measures of CVD are necessary to better characterize risk.
OBJECTIVE: To characterize and compare cardiovascular disease (CVD) risk in HIV-infected and uninfected postmenopausal minority women using the Framingham Risk Score (FRS) as an assessment measure. METHODS: A cross-sectional analysis was performed in 152 (109 HIV+, 43 HIV-) subjects from an existing study cohort of postmenopausal Hispanic and African American women. Data necessary to calculate FRS and menopause features were retrieved by retrospective chart review. Bivariate statistics was used to compare CVD risk factors. Multivariable linear regression was used to determine factors associated with FRS in HIV-infectedwomen. RESULTS: The HIV-infected group was younger, less obese, and with lower rates of diabetes versus controls. In a subset of age-matched participants, median FRS did not differ between groups (14.6 [IQR = 9.1, 21.6] vs. 15.5 [IQR = 12.3, 22.1]; p = 0.73). Fourteen percent of HIV-infectedwomen meeting criteria for the low-risk FRS category (<10%) had a history of CVD, a similar rate as controls. HIV-infectedwomen at intermediate/high CVD risk had higher rates of surgical menopause. According to 2013 clinical guidelines, more than half of HIV-infectedwomen not prescribed statin therapy (52%) were eligible for treatment; however, statin therapy was similarly under-prescribed in uninfected women. CONCLUSIONS: In this study, CVD risk as assessed by the FRS was not significantly different by HIV status. Performance of the FRS may be compromised in postmenopausal HIV-infected minority women. HIV-infected and uninfected women may be undertreated with statin therapy. Large longitudinal cohorts and inclusion of subclinical measures of CVD are necessary to better characterize risk.
Authors: E E A Arts; C Popa; A A Den Broeder; A G Semb; T Toms; G D Kitas; P L van Riel; J Fransen Journal: Ann Rheum Dis Date: 2014-01-03 Impact factor: 19.103
Authors: Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis Journal: N Engl J Med Date: 2003-02-20 Impact factor: 91.245
Authors: Michael T Yin; Chiyuan A Zhang; Donald J McMahon; David C Ferris; Dinaz Irani; Ivelisse Colon; Serge Cremers; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2011-11-16 Impact factor: 5.958
Authors: Michael T Yin; Don J McMahon; David C Ferris; Chiyuan A Zhang; Aimee Shu; Ronald Staron; Ivelisse Colon; Jeffrey Laurence; Jay F Dobkin; Scott M Hammer; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2009-12-04 Impact factor: 5.958
Authors: Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2007-04-26 Impact factor: 91.245
Authors: Hernando Knobel; Carlos Jericó; Milagro Montero; María L Sorli; Manuela Velat; Ana Guelar; Pere Saballs; Juan Pedro-Botet Journal: AIDS Patient Care STDS Date: 2007-07 Impact factor: 5.078
Authors: Julie A Womack; Chung-Chou H Chang; Kaku A So-Armah; Charles Alcorn; Jason V Baker; Sheldon T Brown; Matthew Budoff; Adeel A Butt; Cynthia Gibert; Matthew Bidwell Goetz; John Gottdiener; Stephen Gottlieb; Amy C Justice; David Leaf; Kathleen McGinnis; David Rimland; Maria C Rodriguez-Barradas; Jason Sico; Melissa Skanderson; Hilary Tindle; Russell P Tracy; Alberta Warner; Matthew S Freiberg Journal: J Am Heart Assoc Date: 2014-10-16 Impact factor: 5.501
Authors: Derek Larson; Seung Hyun Won; Anuradha Ganesan; Ryan C Maves; Karl Kronmann; Jason F Okulicz; Xiuping Chu; Christina Schofield; Thomas O'Bryan; Brian K Agan; Robert Deiss Journal: HIV Med Date: 2021-10-26 Impact factor: 3.180
Authors: Katherine Davis; Pablo Perez-Guzman; Annika Hoyer; Ralph Brinks; Edward Gregg; Keri N Althoff; Amy C Justice; Peter Reiss; Simon Gregson; Mikaela Smit Journal: BMC Med Date: 2021-05-13 Impact factor: 8.775
Authors: Titus Msoka; Josephine Rogath; Gary Van Guilder; Gibson Kapanda; Yvo Smulders; Marceline Tutu van Furth; John Bartlett; Michiel van Agtmael Journal: HIV AIDS (Auckl) Date: 2021-06-03